Australia's most trusted
source of pharma news
Posted 28 March 2024 AM
Peak cancer groups have hand-delivered a message to Health and Aged Care Minister Mark Butler calling for urgent expanded access to the PD-1/PD-L1 inhibitor class of drugs for more than 3500 Australians.
The appeal for a new, so-called 'pan tumour' approach to reviewing and funding cancer medicines, follows two submissions made to the PBAC last year by MSD and BMS which would see their blockbuster drugs Keytruda and Opdivo (plus BMS' CTLA-4 inhibitor Yervoy) automatically listed on the PBS at the point of TGA registration.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.